AstraZeneca’s Checkpoint Inhibitor Imfinzi Flops in Cervical Cancer Trial

AstraZeneca’s checkpoint inhibitor Imfinzi (durvalumab) didn’t meet its primary endpoint of improving progression-free survival when compared with chemoradiotherapy (CRT) alone in the treatment of patients with locally advanced cervical cancer,…

Continue ReadingAstraZeneca’s Checkpoint Inhibitor Imfinzi Flops in Cervical Cancer Trial

Argenx’s Phase 3 Data Shows Promise for Subcutaneous Treatment of Generalized Myasthenia Gravis

Argenx has released positive results from a late-stage trial of Vyvgart (efgartigimod alfa-fcab) for the subcutaneous treatment of patients with generalized myasthenia gravis. Source: Drug Industry Daily

Continue ReadingArgenx’s Phase 3 Data Shows Promise for Subcutaneous Treatment of Generalized Myasthenia Gravis

At Public Meeting, Biosimilars Industry Lets FDA Know What’s Still Lacking in Its Communications

The FDA’s communications with the biosimilars industry around inspection delays have been “poor,” and its interaction with that sector of the industry around application-level communications and regulatory science hasn’t been…

Continue ReadingAt Public Meeting, Biosimilars Industry Lets FDA Know What’s Still Lacking in Its Communications